Case Scenarios for Nurses/Case Managers: New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis

Learning Objectives

• Discuss recent advances in the treatment and symptom management of multiple sclerosis
• Describe patient-tailored treatment approaches for modifying the course of the disease and managing symptoms
• Formulate effective management strategies for improving overall outcomes and quality of life for patients with multiple sclerosis

Target Audience

This activity was developed for case managers and nurses. 

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour.

Case Manager Accreditation
This accredited activity has been approved by CCMC for 1.0 hour of continuing education. 
Sponsor code:  CM2428
Approval number is : CM 790001876

Instructions for Credit
There is no fee for this activity. In order to receive credit, participants must listen to this CE activity in its entirety and complete the evaluation at www.mlicme.org/P11039E_quiz.php. Please take a few minutes to complete this evaluation form and your certificate of credit will be e-mailed to you.

For questions regarding the nursing accreditation of this activity, please contact Medical Learning Institute at (609) 333-1693 or cgusack@mlicme.org.

Disclosures
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. 

The associates of the University of Cincinnati, Medical Learning Institute, Inc., the accredited providers for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.

Peer Reviewer Disclosures

• Jayshree Shah, RN, APN-C, MSN, BSN, BS, is on the speaker’s bureau for Bristol-Myers Squibb and Cephalon. She is also on the advisory board for Bristol-Myers Squibb, Celgene, and Novartis.
• Elizabeth Cohen, has nothing to disclose.

Faculty Disclosures

• Daniel Kantor, MD, discloses that he receives honoraria and is on the speakers’ bureau and advisory boards for Allergan, Avanir, Biogen, EMD Serono, Forest, Merck, Questcor, and Teva. He receives research funding from Biogen and Teva.

  
  Disclaimer:  The use of trade names in this presentation is for the learners’ reference only. No promotion or endorsement of any product should be inferred.

Disclaimer
The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines.  No bias towards or promotion for any agent-discussed in this program should be inferred.